Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Like It Or Not, FDA Is At The Center Of Drug Pricing Debate

This article was originally published in The Pink Sheet Daily

Executive Summary

House committees create demanding schedule for CDER's Woodcock, requiring her at two hearings 90 minutes apart.

You may also be interested in...



FDA Sets New Goal For Biosimilar, Drug Promotion Guidances

Agency plans to issue 102 new and revised draft guidances this year, including those on use of multiple endpoints in clinical trials, 180-day exclusivity, and ANDA refuse-to-receive standards.

Biosimilars Forum: How Do You Create A Brand-Generic Coalition? Don’t Talk About Naming

Group of 11 companies is focusing on biosimilar reimbursement and educational issues important to market formation.

US FDA Oncology, Device Centers Developing Public Diagnostic Standards

Pilot program would get around the ‘one drug, one test’ policy, which has created intellectual property issues.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS079131

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel